drugset / Trial / NCT00091585
Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether SNS-595 given intravenously once every 3 weeks is safe.
Timeline
- Start
- 2004-06
- Primary completion
- —
- Completion
- 2006-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vosaroxin | Small molecule | — | Intravenous |